

## **Section: Contact Information**

First Name : **Matthew**  
Last Name : **Ehrhardt**  
Institution : **St. Jude Children's Research Hospital**  
Address 1 : **262 Danny Thomas Place**  
Address 2 : **MS 735**  
City : **Memphis**  
State/Province/Region : **TN**  
Country : **US**  
Zip/Postal Code : **38105**  
Phone Number : **901-595-5847**  
Alternate Phone Number :  
Email Address : [matthew.ehrhardt@stjude.org](mailto:matthew.ehrhardt@stjude.org)

## **Section: Project Requirements and Description**

### ***Group: Requirements to submit AOI***

A comprehensive review of previously published data has been completed. : **Yes**

The specific aims are clear and focused. : **Yes**

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title : **Cost-effective cardiomyopathy surveillance strategies in childhood cancer survivors**

Planned research population (eligibility criteria) :

**5-y survivors of childhood cancer exposed to anthracycline and or radiation affecting the heart**

Proposed specific aims :

**In order to inform the cardiomyopathy surveillance recommendations in the next revision COG Long-Term Follow-Up Guidelines, we propose:**

- 1. To examine the cost-effectiveness of interval screening within the cardiomyopathy risk groups proposed by the International Late Effects of Childhood Cancer Guideline Harmonization Group.**
- 2. Identify cost-effective surveillance echocardiography strategies for childhood cancer survivors stratified by novel and prediction model-based risk groups.**

Will the project require non-CCSS funding to complete? : **No**

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? :

### ***Group: Does this project require contact of CCSS study subjects for:***

Additional self-reported information : **No**

Biological samples : **No**

Medical record data : **No**

If yes to any of the above, please briefly describe. :

***Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)***

Second Malignancy :

Chronic Disease : **Secondary**

Psychology / Neuropsychology :

Genetics :

Cancer Control : **Secondary**

Epidemiology / Biostatistics : **Primary**

**Section: Outcomes or Correlative Factors**

Late mortality : **Primary**

Second Malignancy : **Correlative Factors**

***Group: Health Behaviors***

Tobacco :

Alcohol :

Physical activity :

Medical screening :

Other :

If other, please specify :

***Group: Psychosocial***

Insurance :

Marriage :

Education :

Employment :

Other :

If other, please specify :

***Group: Medical Conditions***

Hearing/Vision/Speech :

Hormonal systems :

Heart and vascular : **Primary**

Respiratory :

Digestive :

Surgical procedures :

Brain and nervous system :

Other :

If other, please specify :

***Group: Medications***

Describe medications :

**Group: Psychologic/Quality of Life**

BSI-18 :

SF-36 :

CCSS-NCQ :

PTS :

PTG :

Other :

If other, please specify :

**Group: Other**

Pregnancy and offspring :

Family history :

Chronic conditions (CTCAE v3) :

Health status :

**Group: Demographic**

Age : **Primary**

Race : **Primary**

Sex : **Primary**

Other :

If other, please specify :

**Group: Cancer treatment**

Chemotherapy : **Correlative Factors**

Radiation therapy : **Correlative Factors**

Surgery :

**Section: Anticipated Sources of Statistical Support**

CCSS Statistical Center : **Yes**

Local institutional statistician :

If local, please provide the name(s) and contact information of the statistician(s) to be involved. :

**CCSS statistical center will be needed to provide risk factor analysis that includes the expansion cohort. This would essentially closely tie in with Dan Mulrooney's open cardiac study.**

**Jennifer Yeh and associates will provide the decision modeling/cost-effectiveness analysis.**

Will this project utilize CCSS biologic samples? : **No**

If yes, which of the following? :

If other, please explain :

**Section: Other General Comments**

Other General Comments :

**Matt Ehrhardt, Jennifer Yeh, Saro Armenian, and Joy Fulbright have been in communication to develop this proposal.**